GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Affymetrix Inc (NAS:AFFX) » Definitions » ROC (Joel Greenblatt) %

Affymetrix (Affymetrix) ROC (Joel Greenblatt) % : 24.54% (As of Dec. 2015)


View and export this data going back to . Start your Free Trial

What is Affymetrix ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Affymetrix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2015 was 24.54%.

The historical rank and industry rank for Affymetrix's ROC (Joel Greenblatt) % or its related term are showing as below:

AFFX's ROC (Joel Greenblatt) % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -15.21
* Ranked among companies with meaningful ROC (Joel Greenblatt) % only.

Affymetrix's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Affymetrix ROC (Joel Greenblatt) % Historical Data

The historical data trend for Affymetrix's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affymetrix ROC (Joel Greenblatt) % Chart

Affymetrix Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -23.89 -41.81 -2.72 3.98 18.04

Affymetrix Quarterly Data
Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.29 35.73 41.87 -20.42 24.54

Competitive Comparison of Affymetrix's ROC (Joel Greenblatt) %

For the Diagnostics & Research subindustry, Affymetrix's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Affymetrix's ROC (Joel Greenblatt) % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Affymetrix's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Affymetrix's ROC (Joel Greenblatt) % falls into.



Affymetrix ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(47.849 + 53.391 + 12.289) - (59.392 + 7.534 + 0)
=46.603

Working Capital(Q: Dec. 2015 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(58.97 + 54.131 + 57.655) - (56.037 + 8.605 + 0)
=106.114

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Affymetrix for the quarter that ended in Dec. 2015 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2015 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2015  Q: Dec. 2015
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=23.936/( ( (21.365 + max(46.603, 0)) + (21 + max(106.114, 0)) )/ 2 )
=23.936/( ( 67.968 + 127.114 )/ 2 )
=23.936/97.541
=24.54 %

Note: The EBIT data used here is four times the quarterly (Dec. 2015) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affymetrix  (NAS:AFFX) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Affymetrix ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Affymetrix's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Affymetrix (Affymetrix) Business Description

Traded in Other Exchanges
N/A
Address
Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.
Executives
Nelson C Chan director C/O SYNAPTICS INCORPORATED, 1251 MCKAY DRIVE, SAN JOSE CA 95131
Merilee Raines director IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092
Gary S Guthart director C/O INTUITIVE SURGICAL INC, 1266 KIFER RD, SUNNYVALE CA 94086
Jami K Nachtsheim director
Riccardo Pigliucci director 9640 TOWNE CENTRE DR, SAN DIEGO CA 92121
Andrew J. Last officer: EVP, Chief Operating Officer 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Gavin Wood officer: EVP, Chief Financial Officer C/O ADAPTIMMUNE THERAPEUTICS PLC, 60 JUBILEE AVE, MILTON PARK, ABINGDON, OXFORDSHIRE X0 OX14 4RX
Frank Witney director, officer: President and CEO 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Fodor Stephen P A director C/O AFFYMETRIX INC, 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Robert Paul Wayman director C/O HEWLETT-PACKARD COMPANY, 3000 HANOVER STREET, PALO ALTO CA 94304
Timothy C Barabe officer: Chief Financial Officer C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Runkel John F Jr officer: EVP and General Counsel C/O INTUITIVE SURGICAL, INC., 1266 KIFER ROAD, SUNNYVALE CA 94086
John D Diekman director C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kevin M King officer: President and CEO C/O AFFYMETRIX, INC., 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Paul Berg director STANFORD UNIVERSITY SCHOOL OF MEDICINE, #B062, STANFORD CA 94305

Affymetrix (Affymetrix) Headlines

From GuruFocus

Affymetrix Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-06-2010

Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 10,000 Shares

By GuruFocus Research GuruFocus Editor 08-24-2010

Affymetrix Inc. (AFFX) CFO Timothy C Barabe buys 5,000 Shares

By GuruFocus Research GuruFocus Editor 11-19-2010